A5029487621- Bladder and Urothelial Cancer Treatments
- Urological Disorders and Treatments
- Urinary and Genital Oncology Studies
- Prostate Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Urologic and reproductive health conditions
- Urinary Bladder and Prostate Research
- Genital Health and Disease
- Testicular diseases and treatments
- Renal cell carcinoma treatment
- Pelvic floor disorders treatments
- Sarcoma Diagnosis and Treatment
- Cancer, Lipids, and Metabolism
- Ureteral procedures and complications
- Hormonal and reproductive studies
- Urinary Tract Infections Management
- Colorectal Cancer Screening and Detection
- Pelvic and Acetabular Injuries
- Renal and related cancers
- Pediatric Urology and Nephrology Studies
- Hernia repair and management
- Cardiac, Anesthesia and Surgical Outcomes
- Statistical Methods in Clinical Trials
- Global Cancer Incidence and Screening
- Tissue Engineering and Regenerative Medicine
University Hospital Frankfurt
2017-2025
Goethe University Frankfurt
2017-2025
Universität Hamburg
2011-2024
University Medical Center Hamburg-Eppendorf
2011-2024
Martini-Klinik
2013-2024
IRCCS Ospedale San Raffaele
2021
Centre Hospitalier de l’Université de Montréal
2021
Medical University of Vienna
2017-2021
Klinik und Poliklinik für Urologie
2013-2019
Cornell University
2012-2018
Abstract Background In-hospital mortality and complication rates after partial radical nephrectomy in patients with history of heart-valve replacement are unknown. Patients Methods Relying on the National Inpatient Sample (2000–2019), kidney cancer undergoing or were stratified according to presence absence replacement. Multivariable logistic Poisson regression models addressed adverse hospital outcomes. Results Overall, 39,673 underwent versus 94,890 nephrectomy. Of those, 248 (0.6%) 676...
PurposeTo assess in-hospital mortality and complication rates after radical cystectomy (RC) in patients with history of heart-valve replacement.Materials methodsUsing the National Inpatient Sample (2000–2019), non-metastatic bladder cancer undergoing RC were stratified according to replacement. Regression models (RM) predicted hospital outcomes.ResultsOf 25,535 patients, 250 (1.0%) harbored Heart-valve replacement older (median 74 vs. 70 years), more frequently male (87.2 80.6%), had...
With approval of novel systemic therapies within the past decade for metastatic hormone-sensitive (mHSPC) and castration-resistant (mCRPC) prostate cancer, patients may receive several therapy lines. However, use these treatments is under an ongoing change. We investigated contemporary treatment trends progression-free (PFS) overall (OS) survival different
To assess cancer-specific mortality (CSM) and other-cause (OCM) rates in patients with rare histological prostate cancer subtypes.
To our knowledge the impact of body mass index on oncologic outcomes in nonmuscle invasive bladder cancer has not been evaluated. We hypothesized that higher is associated with worse patients clinical primary T1 high grade urothelial carcinoma bladder.We retrospectively analyzed data from 892 7 centers. Patients were treated transurethral resection or without intravesical therapy. Body was as a continuous and categorical variable (nonobese-body less than 30 kg/m(2) vs obese-body greater)....
Abstract Purpose: Surveillance of clinical stage I (CSI) testicular germ cell tumors (GCT) is hampered by low sensitivity and specificity current biomarkers for detecting relapses. This study evaluated if serum levels microRNA371a-3p (M371 test) can: (i) Accurately detect relapses, (ii) relapses earlier than conventional technology, (iii) elevated postoperative M371 may predict relapse. Experimental Design: In a multicentric setting, 258 patients with CSI GCT were prospectively followed...
Currently available post hoc phase 3 trial-derived data suggest better cancer-control outcomes in apalutamide-treated metastatic hormone-sensitive prostate cancer (mHSPC) patients achieving an (ultra)low prostate-specific antigen (PSA) nadir. This study aims to validate ultralow PSA nadir cutoffs.
To assess the association between diabetes mellitus (DM) and metformin use with prognosis outcomes of non-muscle-invasive bladder cancer (NMIBC) PATIENTS AND METHODS: We retrospectively evaluated 1117 patients NMIBC treated at four institutions 1996 2007. Cox regression models were used to analyse DM disease recurrence, progression, cancer-specific mortality any-cause mortality.Of patients, 125 (11.1%) had 43 (3.8%) metformin. Within a median (interquartile range) follow-up 64 (22-106)...
Bacillus Calmette-Guérin and intravesical chemotherapy represent viable adjuvant options for intermediate risk nonmuscle invasive bladder cancer. Although bacillus is perceived as less tolerable than chemotherapy, to our knowledge no comparative studies have addressed quality of life issues. We compared the patients with cancer who received gemcitabine or 1/3 dose Calmette-Guérin.Our multicenter, prospective, randomized, phase II study included 120 Of these 88 remained assessable at 1-year...